Activation of Prodrugs by Antibody-Enzyme Conjugates
Monoclonal antibodies (MAbs) against human tumor antigens have been the subject of extensive investigation as carriers of cytotoxic agents to tumor cells. Promising results, both in vitro and in vivo, have been obtained in studies involving immunoconjugates such as MAb-toxins (Vitetta et al., 1987; Blakey et al., 1988), MAb-drugs (Pietersz, 1990; Koppel, 1990), and radiolabeled MAbs (Goldenberg, 1990). Based on these findings, many such conjugates are currently being evaluated in the clinic.
KeywordsH2981 Cell Cytosine Deaminase H2981 Tumor Immunological Specificity Human Tumor Antigen
Unable to display preview. Download preview PDF.
- Bukhari, M.A., Everett, J.L., and Ross, W.C.J. Glucuronic, Sulphuric and Phosphoric Esters of p-Di-2-chloroethylaminophenol. Biochem. Pharm., 21:963.Google Scholar
- Goldenberg, D.M., 1990, Cancer Imaging with Radiolabeled Antibodies,Kluwer Academic Publishers, Boston.Google Scholar
- Senter, P.D., Activation of prodrugs by antibody-enzyme conjugates: A new approach to cancer therapy. FASEB. 4:188.Google Scholar
- Senter, P.D., Schreiber, G.J., Hirschberg, D.L., Ashe, S.A., Hellstrom, K.E., Hellstrom, L, 1990, Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates. Cancer Res., 49:5789.Google Scholar
- Thorpe, P.E., 1985, Antibody carriers of cytotoxic agents in cancer therapy: a review, in: “Monoclonal antibodies’ 84: biological and clinical applications,” Editrice Kurtis, Milan.Google Scholar